Literature DB >> 15895304

Relapse of primary CNS lymphoma after more than 10 years in complete remission.

Ulrich Herrlinger, Holger Hebart, Lothar Kanz, Johannes Dichgans, Michael Weller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15895304     DOI： 10.1007/s00415-005-0854-4

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  12 in total

1.  PCV salvage chemotherapy for recurrent primary CNS lymphoma.

Authors:  U Herrlinger; W Brugger; M Bamberg; W Küker; J Dichgans; M Weller
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

2.  Late relapse of non-Hodgkin's lymphoma after a 28-year disease-free interval: an unusual case.

Authors:  A Isikdogan; O Ayyildiz; A Buyukcelik; M Soker; H Buyukbayram
Journal:  Ann Hematol       Date:  2003-09-05       Impact factor: 3.673

3.  Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

Authors:  Lisa M DeAngelis; Wendy Seiferheld; S Clifford Schold; Barbara Fisher; Christopher J Schultz
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

4.  Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.

Authors:  J Glass; M L Gruber; L Cher; F H Hochberg
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

5.  Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.

Authors:  A Y Lee; J M Connors; P Klimo; S E O'Reilly; R D Gascoyne
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

6.  Treatment for primary CNS lymphoma: the next step.

Authors:  L E Abrey; J Yahalom; L M DeAngelis
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

7.  Long-term survival in primary CNS lymphoma.

Authors:  L E Abrey; L M DeAngelis; J Yahalom
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

8.  Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features.

Authors:  Daphne de Jong; Annuska M Glas; Lucie Boerrigter; Marie-Christine Hermus; Otilia Dalesio; Els Willemse; Petra M Nederlof; Marie José Kersten
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

9.  Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.

Authors:  Hendrik Pels; Ingo G H Schmidt-Wolf; Axel Glasmacher; Holger Schulz; Andreas Engert; Volker Diehl; Anton Zellner; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Martina Deckert; Rolf Fimmers; Christoph Helmstaedter; Aslihan Atasoy; Thomas Klockgether; Uwe Schlegel
Journal:  J Clin Oncol       Date:  2003-11-03       Impact factor: 44.544

10.  Late relapse from complete remission in nodular and diffuse histiocytic lymphoma.

Authors:  G M Mead; F R Mackintosh; J S Burke; S A Rosenberg
Journal:  Cancer       Date:  1983-10-15       Impact factor: 6.860
View more
  2 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

2.  Late relapse in primary central nervous system lymphoma: clonal persistence.

Authors:  Lakshmi Nayak; Cyrus Hedvat; Marc K Rosenblum; Lauren E Abrey; Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2011-03-03       Impact factor: 12.300
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.